Enanta Announces New Data on VIEKIRA PAK in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis

By: via Benzinga
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) announced Saturday, new data from AbbVie's ongoing Phase 3b TOPAZ-II study ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.